SCHEMBL6521167

SCHEMBL6521167

CCCOc1ccc2[nH]c(C(=O)N3C[C@@H](CCl)c4c3cc(O)c3ccccc43)cc2c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 2/20 0.50
KIT P10721 2/20 0.50
FLT1 P17948 2/20 0.50
KDR P35968 2/20 0.50
ABL2 P42684 2/20 0.50
FLT4 P35916 1/20 0.50
DRD3 P35462 4/20 0.41
DRD2 P14416 3/20 0.41
PDGFRB P09619 7/20 0.40
PDGFRA P16234 7/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
BCHE P06276 1/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.40
MAOB P27338 1/20 0.40
ABCB1 P08183 1/20 0.39
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521161 1.00 ADH1A (0.50) ADH1AKITFLT1KDRABL2
SCHEMBL6518437 0.97 ADH1A (0.52) ADH1AKITFLT1KDRABL2
SCHEMBL6518434 0.97 ADH1A (0.52) ADH1AKITFLT1KDRABL2
SCHEMBL6514942 0.93 ADH1A (0.52) ADH1AKITFLT1KDRABL2
SCHEMBL6514946 0.93 ADH1A (0.52) ADH1AKITFLT1KDRABL2
SCHEMBL17801957 0.91 PDGFRB (0.51) ADH1AKITFLT1KDRABL2
SCHEMBL13596672 0.91 PDGFRB (0.51) ADH1AKITFLT1KDRABL2
SCHEMBL6517364 0.90 ADH1A (0.53) ADH1AKITFLT1KDRABL2
SCHEMBL6517359 0.90 ADH1A (0.53) ADH1AKITFLT1KDRABL2
SCHEMBL6514433 0.89 KDM4E (0.52) ADH1AKITFLT1KDRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170232113-A1 QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH, INC. (US) 2017-08-17 US disclosed
US-20050026987-A1 CBI analogues of the duocarmycins and CC-1065 THE SCRIPPS RESEARCH INSTITUTE (US) 2005-02-03 US disclosed
WO-2004101767-A2 CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 THE SCRIPPS RESEARCH INSTITUTE (US) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026987-A1 CBI analogues of the duocarmycins and CC-1065 CCNI, SP1, DCK ADH1A 4729/4885KIT 1086/4885FLT1 4650/4885
US-20170232113-A1 QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF H1-5, H1-4, CD47 ADH1A 1665/4885KIT 2490/4885FLT1 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.